Academic literature on the topic 'Ataxia Telangiectasia and Rad3-related (ATR)'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ataxia Telangiectasia and Rad3-related (ATR).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Ataxia Telangiectasia and Rad3-related (ATR)"
Friesner, Joanna D., Bo Liu, Kevin Culligan, and Anne B. Britt. "Ionizing Radiation–dependent γ-H2AX Focus Formation Requires Ataxia Telangiectasia Mutated and Ataxia Telangiectasia Mutated and Rad3-related." Molecular Biology of the Cell 16, no. 5 (May 2005): 2566–76. http://dx.doi.org/10.1091/mbc.e04-10-0890.
Full textKumbhar, Ramhari, Sophie Vidal-Eychenié, Dimitrios-Georgios Kontopoulos, Marion Larroque, Christian Larroque, Jihane Basbous, Sofia Kossida, Cyril Ribeyre, and Angelos Constantinou. "Recruitment of ubiquitin-activating enzyme UBA1 to DNA by poly(ADP-ribose) promotes ATR signalling." Life Science Alliance 1, no. 3 (June 2018): e201800096. http://dx.doi.org/10.26508/lsa.201800096.
Full textTurner, Thomas, and Thomas Caspari. "When heat casts a spell on the DNA damage checkpoints." Open Biology 4, no. 3 (March 2014): 140008. http://dx.doi.org/10.1098/rsob.140008.
Full textDeHart, Jason L., Joshua L. Andersen, Erik S. Zimmerman, Orly Ardon, Dong Sung An, Jana Blackett, Baek Kim, and Vicente Planelles. "The Ataxia Telangiectasia-Mutated and Rad3-Related Protein Is Dispensable for Retroviral Integration." Journal of Virology 79, no. 3 (February 1, 2005): 1389–96. http://dx.doi.org/10.1128/jvi.79.3.1389-1396.2005.
Full textVidal-Eychenié, Sophie, Chantal Décaillet, Jihane Basbous, and Angelos Constantinou. "DNA structure-specific priming of ATR activation by DNA-PKcs." Journal of Cell Biology 202, no. 3 (July 29, 2013): 421–29. http://dx.doi.org/10.1083/jcb.201304139.
Full textAsmal, M., E. Dean, J. Evans, M. Middleton, and R. Plummer. "VX-970, selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein." Annals of Oncology 26 (March 2015): ii8. http://dx.doi.org/10.1093/annonc/mdv084.4.
Full textTakeuchi, Makoto, Michihiro Tanikawa, Kazunori Nagasaka, Katsutoshi Oda, Yoshiko Kawata, Shinya Oki, Chuwa Agapiti, et al. "Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells." Cancers 11, no. 12 (December 1, 2019): 1913. http://dx.doi.org/10.3390/cancers11121913.
Full textWard, Irene M., Kay Minn, and Junjie Chen. "UV-induced Ataxia-telangiectasia-mutated and Rad3-related (ATR) Activation Requires Replication Stress." Journal of Biological Chemistry 279, no. 11 (January 23, 2004): 9677–80. http://dx.doi.org/10.1074/jbc.c300554200.
Full textTibelius, Alexandra, Joachim Marhold, Hanswalter Zentgraf, Christoph E. Heilig, Heidemarie Neitzel, Bernard Ducommun, Anita Rauch, Anthony D. Ho, Jiri Bartek, and Alwin Krämer. "Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1." Journal of Cell Biology 185, no. 7 (June 22, 2009): 1149–57. http://dx.doi.org/10.1083/jcb.200810159.
Full textPancholi, Neha J., Alexander M. Price, and Matthew D. Weitzman. "Take your PIKK: tumour viruses and DNA damage response pathways." Philosophical Transactions of the Royal Society B: Biological Sciences 372, no. 1732 (September 11, 2017): 20160269. http://dx.doi.org/10.1098/rstb.2016.0269.
Full textDissertations / Theses on the topic "Ataxia Telangiectasia and Rad3-related (ATR)"
Alsubhi, Nouf. "Targeting ataxia telangiectasia-mutated and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized cancer therapy." Thesis, University of Nottingham, 2018. http://eprints.nottingham.ac.uk/52080/.
Full textIchisima, Jose. "Verification and rectification of cell type-specific splicing of a Seckel syndrome-associated ATR mutation using iPS cell model." Kyoto University, 2019. http://hdl.handle.net/2433/243306.
Full textCartwright, Brian. "Exploration of Ataxia Telangiectasia and Rad3-Related’s (ATR’s) Role in Cell Death Regulation: Implications in Development, Cancer, and Stroke." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/etd/3664.
Full textKIDIYOOR, GURURAJ RAO. "ATR MEDIATED REGULATION OF CELLULAR AND NUCLEAR PLASTICITY." Doctoral thesis, Università degli Studi di Milano, 2018. http://hdl.handle.net/2434/561090.
Full textAbu, Sanad Atlal. "Dual inhibition of Ataxia-telangiectasia and Rad3-related (ATR) and Poly-ADP polymerase (PAPR) pathways enhances Topoisomerase l cytotoxicity in colon cancer cell lines:pre- clinical assessment of pathway-specific novel therapeutics." Thesis, McGill University, 2014. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=123053.
Full textManipuler les mécanismes de réparation de l'ADN impliquées dans la réparation de dommage de l'ADN médiatisé de la topoisomérase-1 (Top I) peut renforcer les bienfaits thérapeutiques des poisons Top I. Les inhibiteurs de polymérase poly-ADP ribose (PARP) peuvent augmenter la cytotoxicité de plusieurs agents anticancéreux en inhibant différentes voies de réparation de l'ADN comprenant la réparation par recombinaison homologue (HRR)(1). Cependant, l'inhibition de la PARP peut entraîner une activation compensatoire de la voie ATR, limitant partiellement la sensibilisation des agents chimiothérapiques observés avec les inhibiteurs de PARP. Récemment, un inhibiteur de l'ATR spécifique, VE-821 a démontré une excellente sensibilisation à divers agents chimiothérapiques avec une activité antitumorale préférentielle dans les cellules tumorales par rapport aux cellules normales (2).Lignes cellulaires du cancer du côlon : HCT 116, Lovo (type sauvage de p53) et HT29 (p53 muté) ont été traités avec SN38, l'inhibiteur de la PARP (ABT-888) et/ou l'inhibiteur de l'ATR (VE821) à différentes concentrations. Le dosage de cytotoxicité SRB a été utilisé pour déterminer IC50 de chaque médicament séparément ou en combinaison. Les dommages DNA causés par ces agents ont été quantifiés par phosphorylée-H2AX. Les altérations du cycle cellulaire et des protéines (analyse de l'ouest) ont été déterminées après un traitement médicamenteux.
Shaj, Kavya. "Differing functions of ATR kinase in human epidermal keratinocytes exposed to Ultraviolet B Radiation." Wright State University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=wright156704699234269.
Full textWolf, Horrell Erin M. "Regulation of UV-Protective Pathways Downstream of the Melanocortin 1 Receptor in Melanocytes." UKnowledge, 2016. http://uknowledge.uky.edu/physiology_etds/29.
Full textTayeh, Zainab. "Centrosome integrity as a determinant of replication stress." Doctoral thesis, 2020. http://hdl.handle.net/21.11130/00-1735-0000-0005-1300-5.
Full textBook chapters on the topic "Ataxia Telangiectasia and Rad3-related (ATR)"
Awasthi, Poorwa, Vipin Kumar Yadav, Manisha Dixit, and Amit Kumar. "Ataxia Telangiectasia and Rad3-Related (ATR)." In Encyclopedia of Signaling Molecules, 452–59. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-67199-4_101789.
Full textAwasthi, Poorwa, Vipin Kumar Yadav, Manisha Dixit, and Amit Kumar. "Ataxia Telangiectasia and Rad3-Related (ATR)." In Encyclopedia of Signaling Molecules, 1–9. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4614-6438-9_101789-1.
Full textConference papers on the topic "Ataxia Telangiectasia and Rad3-related (ATR)"
Wilsker, Deborah, Allison M. Marrero, Angie Dull, Thomas D. Pfister, Scott M. Lawrence, John Carter, Michelle Gottholm-Ahalt, et al. "Abstract B24: Ataxia-telangiectasia and Rad3-related (ATR) phosphorylation as a pharmacodynamic biomarker of ATR activation in solid tumor tissue models." In Abstracts: AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; February 28 - March 2, 2016; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3125.cellcycle16-b24.
Full textBateman, Nicholas, Pang-ing Teng, Kelly Conrads, Chad Hamilton, George Maxwell, Christopher Bakkenist, and Thomas Conrads. "Abstract 2747: Pharmacological inhibition of the DNA damage response kinases, ATR (Ataxia telangiectasia and Rad3 related) and ATM (Ataxia telangiectasia mutated), broadly sensitizes diverse subtypes of gynecological cancer cells to ionizing radiation." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2747.
Full textYang, Qingyuan, Ruiqing Yang, Ming Zhan, Narasimharao Nalabothula, and France Carrier. "Abstract 1312: Functional significance for an hnRNP A18 signature RNA motif in the 3'UTR of Ataxia Telangiectasia and RAD3 related (ATR) transcript." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1312.
Full textKrebs, Matthew G., Juanita Lopez, Anthony El-Khoueiry, Yung-Jue Bang, Sophie Postel-Vinay, Wassim Abida, Louise Carter, et al. "Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct026.
Full textYap, Timothy A., Maria J. de Miguel Luken, Brent O'Carrigan, Desam Roda, Dionysis Papadatos-Pastos, David Lorente, Nina Tunariu, et al. "Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-pr14.
Full textTan, David S., Vincent Castonguay, Gregory Cote, Johann S. De Bono, Bassel El-Rayes, Nashat Gabrail, Satoru Iwasa, et al. "EP294/#883 Elimusertib, an oral ataxia telangiectasia and RAD3-related inhibitor, in advanced gynecologic cancers with DNA damage response defects." In IGCS 2022 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-igcs.385.
Full textYap, Timothy, Elizabeth Lee, David Spigel, Elisa Fontana, Martin Højgaard, Stephanie Lheureux, Niharika B. Mettu, et al. "Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations." In Abstracts: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; October 7-10, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1535-7163.targ-21-cc04-01.
Full text